Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

SRXH vs HIMS

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
SRXH
SRx Health Solutions Inc.

Drug Manufacturers - General

HealthcareNYSE • US
Market Cap$1M
5Y Perf.-94.2%
HIMS
Hims & Hers Health, Inc.

Medical - Equipment & Services

HealthcareNYSE • US
Market Cap$6.94B
5Y Perf.-18.8%

SRXH vs HIMS — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
SRXH logoSRXH
HIMS logoHIMS
IndustryDrug Manufacturers - GeneralMedical - Equipment & Services
Market Cap$1M$6.94B
Revenue (TTM)$119M$2.35B
Net Income (TTM)$-11M$128M
Gross Margin19.9%69.7%
Operating Margin-4.9%4.6%
Forward P/E53.9x
Total Debt$39M$1.12B
Cash & Equiv.$2M$229M

SRXH vs HIMSLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

SRXH
HIMS
StockApr 25May 26Return
SRx Health Solution… (SRXH)1005.8-94.2%
Hims & Hers Health,… (HIMS)10081.2-18.8%

Price return only. Dividends and distributions are not included.

Quick Verdict: SRXH vs HIMS

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: HIMS leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. SRx Health Solutions Inc. is the stronger pick specifically for valuation and capital efficiency. As sector peers, any of these can serve as alternatives in the same allocation.
SRXH
SRx Health Solutions Inc.
The Value Play

SRXH is the clearest fit if your priority is value.

  • Better valuation composite
Best for: value
HIMS
Hims & Hers Health, Inc.
The Growth Play

HIMS carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.

  • Rev growth 59.0%, EPS growth -3.8%, 3Y rev CAGR 64.5%
  • 174.3% 10Y total return vs SRXH's -94.6%
  • Lower volatility, beta 2.40, current ratio 1.90x
Best for: growth exposure and long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthHIMS logoHIMS59.0% revenue growth vs SRXH's 28.4%
ValueSRXH logoSRXHBetter valuation composite
Quality / MarginsHIMS logoHIMS5.5% margin vs SRXH's -9.4%
DividendsTieNeither stock pays a meaningful dividend
Momentum (1Y)HIMS logoHIMS-45.7% vs SRXH's -86.7%
Efficiency (ROA)HIMS logoHIMS6.0% ROA vs SRXH's -22.4%, ROIC 10.7% vs -18.1%

SRXH vs HIMS — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLHIMSLAGGINGSRXH

Income & Cash Flow (Last 12 Months)

HIMS leads this category, winning 4 of 4 comparable metrics.

HIMS is the larger business by revenue, generating $2.3B annually — 19.7x SRXH's $119M. HIMS is the more profitable business, keeping 5.5% of every revenue dollar as net income compared to SRXH's -9.4%.

MetricSRXH logoSRXHSRx Health Soluti…HIMS logoHIMSHims & Hers Healt…
RevenueTrailing 12 months$119M$2.3B
EBITDAEarnings before interest/tax$164M
Net IncomeAfter-tax profit$128M
Free Cash FlowCash after capex$73M
Gross MarginGross profit ÷ Revenue+19.9%+69.7%
Operating MarginEBIT ÷ Revenue-4.9%+4.6%
Net MarginNet income ÷ Revenue-9.4%+5.5%
FCF MarginFCF ÷ Revenue+1.3%+3.1%
Rev. Growth (YoY)Latest quarter vs prior year+28.4%
EPS Growth (YoY)Latest quarter vs prior year-27.3%
HIMS leads this category, winning 4 of 4 comparable metrics.

Valuation Metrics

SRXH leads this category, winning 3 of 3 comparable metrics.
MetricSRXH logoSRXHSRx Health Soluti…HIMS logoHIMSHims & Hers Healt…
Market CapShares × price$1M$6.9B
Enterprise ValueMkt cap + debt − cash$29M$7.8B
Trailing P/EPrice ÷ TTM EPS-0.17x52.71x
Forward P/EPrice ÷ next-FY EPS est.53.94x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple44.46x
Price / SalesMarket cap ÷ Revenue0.02x2.96x
Price / BookPrice ÷ Book value/share12.83x
Price / FCFMarket cap ÷ FCF1.21x93.85x
SRXH leads this category, winning 3 of 3 comparable metrics.

Profitability & Efficiency

HIMS leads this category, winning 4 of 6 comparable metrics.

On the Piotroski fundamental quality scale (0–9), HIMS scores 4/9 vs SRXH's 3/9, reflecting mixed financial health.

MetricSRXH logoSRXHSRx Health Soluti…HIMS logoHIMSHims & Hers Healt…
ROE (TTM)Return on equity+23.7%
ROA (TTM)Return on assets-22.4%+6.0%
ROICReturn on invested capital-18.1%+10.7%
ROCEReturn on capital employed-98.8%+10.9%
Piotroski ScoreFundamental quality 0–934
Debt / EquityFinancial leverage2.07x
Net DebtTotal debt minus cash$37M$892M
Cash & Equiv.Liquid assets$2M$229M
Total DebtShort + long-term debt$39M$1.1B
Interest CoverageEBIT ÷ Interest expense-2.83x
HIMS leads this category, winning 4 of 6 comparable metrics.

Total Returns (Dividends Reinvested)

HIMS leads this category, winning 6 of 6 comparable metrics.

A $10,000 investment in HIMS five years ago would be worth $25,051 today (with dividends reinvested), compared to $541 for SRXH. Over the past 12 months, HIMS leads with a -45.7% total return vs SRXH's -86.7%. The 3-year compound annual growth rate (CAGR) favors HIMS at 31.4% vs SRXH's -62.2% — a key indicator of consistent wealth creation.

MetricSRXH logoSRXHSRx Health Soluti…HIMS logoHIMSHims & Hers Healt…
YTD ReturnYear-to-date-52.5%-19.5%
1-Year ReturnPast 12 months-86.7%-45.7%
3-Year ReturnCumulative with dividends-94.6%+126.8%
5-Year ReturnCumulative with dividends-94.6%+150.5%
10-Year ReturnCumulative with dividends-94.6%+174.3%
CAGR (3Y)Annualised 3-year return-62.2%+31.4%
HIMS leads this category, winning 6 of 6 comparable metrics.

Risk & Volatility

Evenly matched — SRXH and HIMS each lead in 1 of 2 comparable metrics.

SRXH is the less volatile stock with a -0.32 beta — it tends to amplify market swings less than HIMS's 2.40 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. HIMS currently trades 38.2% from its 52-week high vs SRXH's 9.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricSRXH logoSRXHSRx Health Soluti…HIMS logoHIMSHims & Hers Healt…
Beta (5Y)Sensitivity to S&P 500-0.32x2.40x
52-Week HighHighest price in past year$1.25$70.43
52-Week LowLowest price in past year$0.08$13.74
% of 52W HighCurrent price vs 52-week peak+9.0%+38.2%
RSI (14)Momentum oscillator 0–10041.052.8
Avg Volume (50D)Average daily shares traded22.0M35.4M
Evenly matched — SRXH and HIMS each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.
MetricSRXH logoSRXHSRx Health Soluti…HIMS logoHIMSHims & Hers Healt…
Analyst RatingConsensus buy/hold/sellHold
Price TargetConsensus 12-month target$29.67
# AnalystsCovering analysts19
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%+1.3%
Insufficient data to determine a leader in this category.
Key Takeaway

HIMS leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). SRXH leads in 1 (Valuation Metrics). 1 tied.

Best OverallHims & Hers Health, Inc. (HIMS)Leads 3 of 6 categories
Loading custom metrics...

SRXH vs HIMS: Frequently Asked Questions

8 questions · data-driven answers · updated daily

01

Is SRXH or HIMS a better buy right now?

For growth investors, Hims & Hers Health, Inc.

(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus 28. 4% for SRx Health Solutions Inc. (SRXH). Hims & Hers Health, Inc. (HIMS) offers the better valuation at 52. 7x trailing P/E (53. 9x forward), making it the more compelling value choice. Analysts rate Hims & Hers Health, Inc. (HIMS) a "Hold" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — SRXH or HIMS?

Over the past 5 years, Hims & Hers Health, Inc.

(HIMS) delivered a total return of +150. 5%, compared to -94. 6% for SRx Health Solutions Inc. (SRXH). Over 10 years, the gap is even starker: HIMS returned +174. 3% versus SRXH's -94. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — SRXH or HIMS?

By beta (market sensitivity over 5 years), SRx Health Solutions Inc.

(SRXH) is the lower-risk stock at -0. 32β versus Hims & Hers Health, Inc. 's 2. 40β — meaning HIMS is approximately -844% more volatile than SRXH relative to the S&P 500.

04

Which is growing faster — SRXH or HIMS?

By revenue growth (latest reported year), Hims & Hers Health, Inc.

(HIMS) is pulling ahead at 59. 0% versus 28. 4% for SRx Health Solutions Inc. (SRXH). On earnings-per-share growth, the picture is similar: SRx Health Solutions Inc. grew EPS 74. 1% year-over-year, compared to -3. 8% for Hims & Hers Health, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — SRXH or HIMS?

Hims & Hers Health, Inc.

(HIMS) is the more profitable company, earning 5. 5% net margin versus -9. 4% for SRx Health Solutions Inc. — meaning it keeps 5. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HIMS leads at 5. 2% versus -4. 9% for SRXH. At the gross margin level — before operating expenses — HIMS leads at 59. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Which pays a better dividend — SRXH or HIMS?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

07

Is SRXH or HIMS better for a retirement portfolio?

For long-horizon retirement investors, SRx Health Solutions Inc.

(SRXH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 32)). Hims & Hers Health, Inc. (HIMS) carries a higher beta of 2. 40 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SRXH: -94. 6%, HIMS: +174. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

08

What are the main differences between SRXH and HIMS?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

SRXH

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 14%
Run This Screen
Stocks Like

HIMS

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 14%
  • Net Margin > 5%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform SRXH and HIMS on the metrics below

Revenue Growth>
%
(SRXH: 28.4% · HIMS: 28.4%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.